ERBB2 and breast carcinoma: ERBB2(HER2) amplification in breast cancer was also recapitulated as a biomarker of sensitivity to the dual EGFR/ERBB2 inhibitor lapatinib (Figure 4—figure supplement 3H; Konecny et al., 2006).